Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. Aug 12, 2024 04:22PM
Citius Pharmaceuticals (CTXR) Announces TenX Keane Shareholder Approval of Merger with Citius Oncology Aug 5, 2024 08:02AM
Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc. Aug 5, 2024 08:00AM
Citius Pharmaceuticals (CTXR) to Merge Wholly Owned Subsidiary with TenX Keane Acquisition (TENK) to Form Publicly Listed Citius Oncology, Inc. Oct 24, 2023 07:31AM
Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc. Oct 24, 2023 07:30AM


Oct 18, 2022 02:20PM TenX Keane Acquisition Announces Closing of $66 Million Initial Public Offering, Including Partial Exercise of Underwriter’s Over-Allotment Option
Oct 18, 2022 02:20PM TenX Keane Acquisition Announces Closing of $66 Million Initial Public Offering, Including Partial Exercise of Underwriter’s Over-Allotment Option
Oct 14, 2022 05:20AM TenX Keane Acquisition (TENKU) Prices 6M Unit IPO at $10/unit
Oct 13, 2022 06:00PM TenX Keane Acquisition Announces Pricing of $60 Million Initial Public Offering
Jun 30, 2021 06:07AM TenX Keane Acquisition (TENKU) Announces 5M Unit IPO at $10/unit